Prognostic value of S100/CD31 and S100/podoplanin double immunostaining in mucosal malignant melanoma of the head and neck

Wermker, Kai; Brauckmann, Till; Klein, Martin; Haßfeld, Stefan; Schulze, Hans‐Joachim; Hallermann, Christian

doi:10.1002/hed.23761

Cited by 12 publications

(4 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Distant metastasis is the limiting factor for long‐term survival. Recently, Wermker et al evaluated the outcome and value of some prognostic factors in a series of 42 patients with PMM of the head and neck; age above 70 years, occurrence of distant metastasis, and lymphovascular invasion were significantly associated with unfavorable outcome and shorter DSS time. Double immunostaining for S‐100 protein/podoplanin and S‐100 protein/CD3 may facilitate recognition of lymphovascular invasion, although widespread use of these diagnostic immunohistochemical procedures seems unlikely.…”

Section: Prognosismentioning

confidence: 99%

Update on primary head and neck mucosal melanoma

et al. 2015

View full text Add to dashboard Cite

Primary mucosal melanomas (PMMs) of the head and neck are uncommon malignancies that arise mainly in the nasal cavity and paranasal sinuses, followed by the oral cavity. The mainstay of treatment is radical surgical resection followed by adjuvant radiotherapy in selected patients with high-risk features. Multimodality therapy has not been well studied and is not standardized. Adjuvant radiotherapy seems to improve locoregional control but does not improve overall survival (OS). Elective neck dissection is advocated in patients with oral PMM. Systemic therapy should be considered only for patients with metastatic or unresectable locoregional disease. Despite improvements in the field of surgery, radiotherapy, and systemic therapy, patients with PMM still face a very unfavorable prognosis (5-year disease-free survival [DFS] <20%) with high rates of locoregional recurrence and distant metastasis. The present review aims to summarize the current state of knowledge on the molecular biology, pathological diagnosis, and management of this disease.

show abstract

Section: Prognosismentioning

confidence: 99%

Update on primary head and neck mucosal melanoma

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Recently, Wermker et al [15] analyzed the data of 42 patients with primary mucosal melanoma of the head and neck and determined a few prognostic factors as follows: age > 70 years, the presence of distant metastasis, and lymphovascular invasion, all of which were important factors associated with unfavorable outcomes and decreased DSS. Oral mucosal melanoma is rarer but much more aggressive than cutaneous melanoma, with a poorer prognosis.…”

Section: Discussionmentioning

confidence: 99%

Primary amelanotic melanoma of the mandibular gingiva

Kim

Chang

et al. 2020

Arch Craniofac Surg

View full text Add to dashboard Cite

Oral mucosal melanoma is a very rare type of malignant melanoma, the characteristics of which differ from those of cutaneous melanoma. Primary amelanotic melanoma of the mandibular gingiva, which can invade the mandibular bone, is very rare worldwide. Here, we report a case in which we performed a reconstruction of the mandible and gingiva using the fibula osteocutaneous free flap procedure to treat a patient diagnosed with a primary amelanotic melanoma of the mandibular gingiva. The procedure was successful, and no recurrence was observed 10 months after surgery. Oral mucosal melanoma has a much poorer prognosis and a lower 5-year survival rate than cutaneous melanoma. However, recently, immunomodulatory therapies for mutations in melanocytic lesions have been used effectively to treat the increasing number of patients developing this type of melanoma, thus improving the prognosis of patients with oral mucosal melanoma.

show abstract

“…The expression of podoplanin and CD13 in combination with S100 has been useful in the evaluation of lymph vessel and blood vessel invasion. Both markers are related to a poorer prognosis [75].…”

Section: Histological Diagnosismentioning

confidence: 99%

Mucosal Melanoma of the Head and Neck: From Diagnosis to Treatment

Mendonça¹,

Soffientini²,

Barbosa³

et al. 2021

Melanoma

View full text Add to dashboard Cite

Mucosal melanomas of the head and neck are very rare malignancies that present with aggressive behavior and poor prognosis. Usually diagnosed at advanced stages, thus presenting macroscopically as aggressive nodular neoplasms arising from the mucosa; few cases are detected in situ. Tumor staging for mucosal melanoma remains a challenge. Several staging systems have been suggested, including tumornodal-metastases (TNM) staging systems, but none are frequently used. There is no clear consensus on the management of head and neck mucosal melanoma, which reflects the rare nature of the disease and complexity of the anatomic site. The late diagnosis, frequently presenting at an advanced stage, denotes the aggressive nature of the disease. Currently, early detection and surgical excision is considered the primary method of treatment. The multidisciplinary team approach can help reduce morbidity and mortality once optimize treatment, reduce costs and minimize adverse events, while maximizing the chances of recovery.

show abstract

Prognostic value of S100/CD31 and S100/podoplanin double immunostaining in mucosal malignant melanoma of the head and neck

Abstract: S100/podoplanin and S100/CD31 double immunostaining detect reliable LVI and BVI in head and neck mucosal melanoma and both are associated significantly with worse prognosis.

Cited by 12 publications

References 39 publications

Update on primary head and neck mucosal melanoma

Update on primary head and neck mucosal melanoma

Primary amelanotic melanoma of the mandibular gingiva

Mucosal Melanoma of the Head and Neck: From Diagnosis to Treatment

Contact Info

Product

Resources

About